Covadonga Paneda - Altamira Therapeutics Chief Officer
| CYTO Stock | USD 0.43 0.01 2.38% |
Executive
Covadonga Paneda is Chief Officer of Altamira Therapeutics
| Age | 50 |
| Address | Clarendon House, Hamilton, Bermuda, HM 11 |
| Phone | 441 295 5950 |
| Web | https://altamiratherapeutics.com |
Altamira Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.5715) % which means that it has lost $0.5715 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (3.6878) %, meaning that it created substantial loss on money invested by shareholders. Altamira Therapeutics' management efficiency ratios could be used to measure how well Altamira Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of the 25th of November 2024, Return On Tangible Assets is likely to drop to -2.01. In addition to that, Return On Capital Employed is likely to grow to -0.83. At this time, Altamira Therapeutics' Debt To Assets are very stable compared to the past year. As of the 25th of November 2024, Asset Turnover is likely to grow to 0.05, while Total Assets are likely to drop about 7.3 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Valerie Morisset | Eliem Therapeutics | 54 | |
| David Ege | Seres Therapeutics | 49 | |
| Alpa Parikh | Lumos Pharma | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| MD FAAP | Lumos Pharma | N/A | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Michael Hassman | Scpharmaceuticals | N/A | |
| SPHR SHRMSCP | Seres Therapeutics | 52 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Kim Fox | Milestone Pharmaceuticals | N/A | |
| RPh Young | Seres Therapeutics | 57 | |
| Eddie MBA | Lumos Pharma | N/A | |
| John PharmD | Scpharmaceuticals | N/A | |
| Steve Parsons | Scpharmaceuticals | N/A | |
| Roshan Girglani | Milestone Pharmaceuticals | N/A | |
| Nicole Esq | HCW Biologics | N/A | |
| JD Esq | Seres Therapeutics | 69 | |
| Matthew Henn | Seres Therapeutics | 49 | |
| Lee Flowers | HCW Biologics | 78 | |
| Jeffrey Nelson | Milestone Pharmaceuticals | 43 | |
Management Performance
| Return On Equity | -3.69 | ||||
| Return On Asset | -0.57 |
Altamira Therapeutics Leadership Team
Elected by the shareholders, the Altamira Therapeutics' board of directors comprises two types of representatives: Altamira Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Altamira. The board's role is to monitor Altamira Therapeutics' management team and ensure that shareholders' interests are well served. Altamira Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Altamira Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Covadonga Paeda, Chief Officer | ||
| Covadonga Paneda, Chief Officer | ||
| Jean Lechance, Unit Bus | ||
| Thomas Meyer, President, Founder | ||
| Samuel MD, Chief Officer | ||
| Marcel CPA, Chief Officer |
Altamira Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Altamira Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -3.69 | ||||
| Return On Asset | -0.57 | ||||
| Current Valuation | 1.96 M | ||||
| Shares Outstanding | 3.78 M | ||||
| Shares Owned By Insiders | 0.52 % | ||||
| Shares Owned By Institutions | 3.13 % | ||||
| Number Of Shares Shorted | 31.09 K | ||||
| Price To Book | 0.25 X | ||||
| Price To Sales | 0.64 X | ||||
| Gross Profit | (2.18 M) |
Pair Trading with Altamira Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Altamira Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Altamira Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Altamira Stock
| 0.71 | ME | 23Andme Holding | PairCorr |
| 0.92 | VALN | Valneva SE ADR | PairCorr |
| 0.75 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
Moving against Altamira Stock
| 0.66 | KZR | Kezar Life Sciences | PairCorr |
| 0.55 | MLYS | Mineralys Therapeutics, | PairCorr |
| 0.39 | MDGL | Madrigal Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Altamira Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Altamira Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Altamira Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Altamira Therapeutics to buy it.
The correlation of Altamira Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Altamira Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Altamira Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Altamira Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Altamira Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Altamira Stock, please use our How to Invest in Altamira Therapeutics guide.You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Altamira Therapeutics. If investors know Altamira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Altamira Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 1.82 | Revenue Per Share 0.917 | Quarterly Revenue Growth (0.64) | Return On Assets (0.57) | Return On Equity (3.69) |
The market value of Altamira Therapeutics is measured differently than its book value, which is the value of Altamira that is recorded on the company's balance sheet. Investors also form their own opinion of Altamira Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Altamira Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Altamira Therapeutics' market value can be influenced by many factors that don't directly affect Altamira Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Altamira Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Altamira Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Altamira Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.